A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Conditions

• Melanoma
• Metastatic Melanoma
• Advanced Solid Tumor
• Hepatocellular Carcinoma

Interventions

• OTHER: Observational study with no interventions

Sponsor

Replimune, Inc.